Back to Search
Start Over
Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Withdrawal Is Associated with Higher Mortality in Hospitalized Patients with COVID-19
- Source :
- Dipòsit Digital de la UB, Universidad de Barcelona, Journal of Clinical Medicine, Vol 10, Iss 2642, p 2642 (2021), Journal of clinical medicine, r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe, instname, Journal of Clinical Medicine, Volume 10, Issue 12, Journal of Clinical Medicine 10(12), 2642 (2021), Helvia: Repositorio Institucional de la Universidad de Córdoba, Universidad de Córdoba, r-FISABIO. Repositorio Institucional de Producción Científica, Helvia. Repositorio Institucional de la Universidad de Córdoba
- Publication Year :
- 2021
- Publisher :
- MDPI AG, 2021.
-
Abstract
- Our main aim was to describe the effect on the severity of ACEI (angiotensin-converting enzyme inhibitor) and ARB (angiotensin II receptor blocker) during COVID-19 hospitalization. A retrospective, observational, multicenter study evaluating hospitalized patients with COVID-19 treated with ACEI/ARB. The primary endpoint was the incidence of the composite outcome of prognosis (IMV (invasive mechanical ventilation), NIMV (non-invasive mechanical ventilation), ICU admission (intensive care unit), and/or all-cause mortality). We evaluated both outcomes in patients whose treatment with ACEI/ARB was continued or withdrawn. Between February and June 2020, 11,205 patients were included, mean age 67 years (SD = 16.3) and 43.1% female<br />2162 patients received ACEI/ARB treatment. ACEI/ARB treatment showed lower all-cause mortality (p &lt<br />0.0001). Hypertensive patients in the ACEI/ARB group had better results in IMV, ICU admission, and the composite outcome of prognosis (p &lt<br />0.0001 for all). No differences were found in the incidence of major adverse cardiovascular events. Patients previously treated with ACEI/ARB continuing treatment during hospitalization had a lower incidence of the composite outcome of prognosis than those whose treatment was withdrawn (RR 0.67, 95%CI 0.63–0.76). ARB was associated with better survival than ACEI (HR 0.77, 95%CI 0.62–0.96). ACEI/ARB treatment during COVID-19 hospitalization was associated with protection on mortality. The benefits were greater in hypertensive, those who continued treatment, and those taking ARB.
- Subjects :
- medicine.medical_specialty
Angiotensin receptor
Coronavirus disease 2019 (COVID-19)
Pronòstic mèdic
medicine.medical_treatment
MACE
030204 cardiovascular system & hematology
urologic and male genital diseases
Pacients hospitalitzats
Article
Hospital patients
law.invention
ACEI, ARB, COVID-19, MACE, prognosis
03 medical and health sciences
0302 clinical medicine
COVID‐19
law
Internal medicine
medicine
Clinical endpoint
030212 general & internal medicine
cardiovascular diseases
Mechanical ventilation
biology
business.industry
Incidence (epidemiology)
COVID-19
Angiotensin-converting enzyme
General Medicine
ARB
Prognosis
Intensive care unit
female genital diseases and pregnancy complications
Hospitals
biology.protein
Medicine
prognosis
business
Mace
ACEI
Subjects
Details
- Language :
- English
- ISSN :
- 20770383
- Database :
- OpenAIRE
- Journal :
- Dipòsit Digital de la UB, Universidad de Barcelona, Journal of Clinical Medicine, Vol 10, Iss 2642, p 2642 (2021), Journal of clinical medicine, r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe, instname, Journal of Clinical Medicine, Volume 10, Issue 12, Journal of Clinical Medicine 10(12), 2642 (2021), Helvia: Repositorio Institucional de la Universidad de Córdoba, Universidad de Córdoba, r-FISABIO. Repositorio Institucional de Producción Científica, Helvia. Repositorio Institucional de la Universidad de Córdoba
- Accession number :
- edsair.doi.dedup.....c1e064a11c5c931a2fed019fb8c59d95